Intensity Therapeutics, INC 8-K filings

Intensity Therapeutics announced the resumption of enrollment in its Phase 3 soft tissue sarcoma study and restarted patient treatment in its Phase 2 triple-negative breast cancer trial, alongside its second quarter 2026 financial results.

Intensity Therapeutics, Inc. announced the results of its annual meeting, with stockholders voting to elect directors, ratify the independent auditor, and approve amendments to stock incentive and purchase plans.

Intensity Therapeutics reported Q1 2026 financial results, highlighting positive preliminary data from the INVINCIBLE-4 study in triple-negative breast cancer and plans to resume enrollment in the INVINCIBLE-3 study.

Intensity Therapeutics announced its 2025 year-end financial results, highlighting clinical advancements for INT230-6 and an extended cash runway into Q2 2027.

Intensity Therapeutics, Inc. has increased its at-the-market offering program capacity to $60.0 million to enhance financial flexibility.

Intensity Therapeutics announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.

Intensity Therapeutics, Inc. furnished an updated financial highlights slide for the period ending December 31, 2025, noting the figures are unaudited and preliminary.

Intensity Therapeutics, Inc. will implement a 1-for-25 reverse stock split to boost its share price and maintain Nasdaq listing compliance.

Intensity Therapeutics, Inc. received a 180-day extension until June 1, 2026, to regain compliance with Nasdaq's minimum $1.00 bid price requirement, avoiding immediate delisting.

Intensity Therapeutics, Inc. has increased the capacity of its at-the-market offering program to $30 million to enhance financial flexibility.

Intensity Therapeutics announced its third quarter 2025 financial results, provided a corporate update on its clinical trials, and extended its cash runway into Q1 2027.

Intensity Therapeutics, a late-stage clinical biotech, announced the pricing of a $4 million registered direct offering to fund clinical trials and extend its cash runway.

Intensity Therapeutics, Inc. stockholders approved a reverse stock split proposal and an adjournment proposal at a special meeting held on October 22, 2025.

Intensity Therapeutics announced a pathological complete response in its INVINCIBLE-4 study but paused new patient enrollment due to localized skin irritation.

Intensity Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a recent capital raise and a bylaw amendment.

Intensity Therapeutics reports Q2 2025 financial results, highlighting over $11 million raised and an extended cash runway into the second half of 2026, despite pausing enrollment in one key clinical study.

Intensity Therapeutics, a late-stage clinical biotechnology company, successfully raised $6.6 million in July 2025 through an At-the-Market offering, extending its cash runway into the second half of 2026.

Intensity Therapeutics, Inc. announced the results of its annual meeting of stockholders held on July 17, 2025, where a Class II director was elected and the independent registered public accounting firm was ratified.

Intensity Therapeutics, a late-stage clinical biotechnology company, successfully closed a public offering of common stock, raising approximately $1.9 million in net proceeds to fund its ongoing clinical trials for cancer therapies.

Intensity Therapeutics, Inc. has received a notice from Nasdaq regarding its failure to maintain the minimum $1.00 closing bid price requirement, initiating a 180-day grace period to regain compliance.

Intensity Therapeutics, Inc. received a Nasdaq notification regarding non-compliance with minimum stockholders' equity requirements, potentially leading to delisting.

Intensity Therapeutics announced its first quarter 2025 financial results, highlighting progress in its clinical programs but also a pause in new site activations and patient enrollment for the INVINCIBLE-3 sarcoma study due to funding limitations.

Intensity Therapeutics has announced a $2.35 million public offering to fund the enrollment of patients in the INVINCIBLE-4 Study, treatment of existing patients in the INVINCIBLE-3 Study, and for general corporate purposes.

Intensity Therapeutics announces a pause in new patient enrollment for its Phase 3 sarcoma trial due to funding constraints, while showcasing the potential of its INT230-6 drug in solid tumor treatment.

Intensity Therapeutics announced its 2024 year-end financial results and provided a corporate update, highlighting progress in its INVINCIBLE-3 and INVINCIBLE-4 studies.

Intensity Therapeutics has entered into a securities purchase agreement for a $3 million registered direct offering and concurrent private placement to a single healthcare focused institutional investor.

Intensity Therapeutics announced its third quarter 2024 financial results, highlighting progress in clinical trials for its cancer therapies and regulatory approvals in multiple countries.

Intensity Therapeutics has granted stock options to its Chief Financial Officer and Principal Accounting Officer to incentivize and retain them.

Intensity Therapeutics announced its second quarter 2024 financial results, highlighted by the first patient dosed in a Phase 3 sarcoma study and a new collaboration for a breast cancer study.

Intensity Therapeutics held its annual meeting where stockholders approved the 2024 Employee Stock Purchase Plan and elected two Class I directors.